bromocriptine has been researched along with Insulin Resistance in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 5 (15.63) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 11 (34.38) | 24.3611 |
| 2020's | 7 (21.88) | 2.80 |
| Authors | Studies |
|---|---|
| Baumgartner, AD; Gross, S; Lyon, E; Nadeau, KJ; Polsky, S; Schafer, M; Schauer, IE; Snell-Bergeon, JK; Tell, SS; Vigers, T | 1 |
| Basiak, M; Krysiak, R; Okopień, B; Szkróbka, W | 1 |
| Bondareva, VM; Derkach, KV; Shpakov, AO | 1 |
| Cincotta, AH | 1 |
| Bloomgarden, Z | 1 |
| Barra, C; Conde, SV; Costa, A; Gasparini, P; Marques, D; Matafome, P; Melo, BF; Rodrigues, T; Rosendo-Silva, D; Sacramento, JF; Seiça, R; Tavares, G | 1 |
| Cincotta, AH; Ezrokhi, M; Luo, S; Zhang, Y | 1 |
| Chamarthi, B; Cincotta, AH | 1 |
| Carvalho, JC; Conceição, EP; de Oliveira, E; Lima, NS; Lisboa, PC; Moura, EG; Nogueira-Neto, JF; Peixoto-Silva, N | 1 |
| Figueroa-Núñez, C; González, E; Gutierrez, M; Hernán Martínez, J; Mangual-García, M; Mansilla-Letelier, P; Miranda, Mde L; Palermo-Garofalo, C; Sánchez, A; Santiago, M; Torres, O; Trinidad, R | 1 |
| Krysiak, R; Okopien, B | 1 |
| Bondareva, VM; Derkach, KV; Moyseyuk, IV; Shpakov, AO | 1 |
| Bahler, L; Booij, J; Hoekstra, JB; Holleman, F; Soeters, MR; Verberne, HJ | 1 |
| Schwartz, SS; Zangeneh, F | 1 |
| Barbosa, FR; Domingues, RC; dos Santos Silva, CM; Fontes, R; Gadelha, MR; Lima, GA; Warszawski, L | 1 |
| Berinder, K; Hall, K; Höybye, C; Hulting, AL; Nyström, T | 1 |
| Bell, DS | 1 |
| de Leeuw van Weenen, JE; Parlevliet, ET; Pijl, H; Romijn, JA; Schröder-van der Elst, JP; van den Berg, SA; Willems van Dijk, K | 1 |
| Hashimoto, S; Midorikawa, S; Sanada, H; Watanabe, T; Yatabe, J | 1 |
| Akalin, S; Akpinar, I; Deyneli, O; Gözü, H; Haklar, G; Sezgin, O; Yavuz, D; Yildiz, E | 1 |
| Hayashi, K; Iigaya, K; Kumagai, H; Onami, T; Saruta, T | 1 |
| Frölich, M; Kok, P; Meinders, AE; Pijl, H; Roelfsema, F; Stokkel, MP; van Pelt, J | 1 |
| Colao, A; Di Somma, C; Lombardi, G; Pivonello, R; Savastano, S; Tauchmanovà, L | 1 |
| Cincotta, AH; Meier, AH | 1 |
| Cincotta, AH; Luo, S; Meier, AH | 1 |
| Cincotta, AH; Liang, Y; Luo, S | 1 |
| Cincotta, AH; Luo, J; Luo, S | 1 |
| Iwamoto, Y; Kawahara, R; Wasada, T | 1 |
| Reaven, GM | 1 |
| Cincotta, AH; Meier, AH; Schiller, BC | 1 |
| Komatsu, M; Saito, S | 1 |
| Cabezas-Cerrato, J; De la Fuente, A; García López, JM; Gaudiero, GJ; Mato Mato, JA; Odriozola, A; Tomé, MA | 1 |
4 review(s) available for bromocriptine and Insulin Resistance
| Article | Year |
|---|---|
Brain Dopamine-Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects.
Topics: Animals; Brain; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dopamine; Dopamine Agonists; Insulin; Insulin Resistance; Insulin, Regular, Human; Metabolic Syndrome | 2023 |
Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Bromocriptine; Circadian Clocks; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dopamine Agonists; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Dopamine D2; Suprachiasmatic Nucleus | 2016 |
Why does quick-release bromocriptine decrease cardiac events?
Topics: Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Oxidative Stress; Postprandial Period | 2011 |
[Hypertension in acromegaly].
Topics: Acromegaly; Blood Pressure; Bromocriptine; Circadian Rhythm; Human Growth Hormone; Humans; Hyperinsulinism; Hypertension; Insulin Resistance; Insulin-Like Growth Factor I; Kidney Tubules, Proximal; Octreotide; Plasma Volume; Sodium; Stroke; Sympathetic Nervous System; Vascular Resistance | 2004 |
6 trial(s) available for bromocriptine and Insulin Resistance
| Article | Year |
|---|---|
Bromocriptine quick-release as adjunct therapy in youth and adults with type 1 diabetes: A randomized, placebo-controlled crossover study.
Topics: Adolescent; Adult; Blood Glucose; Blood Glucose Self-Monitoring; Bromocriptine; Child; Creatinine; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Insulin; Insulin Resistance; Lipids; Middle Aged; Young Adult | 2022 |
Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Treatment Outcome | 2017 |
Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Topics: Adult; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipids; Middle Aged; Prolactin; Risk Factors | 2015 |
Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
Topics: Adiponectin; Adult; Body Weight; Bromocriptine; Dopamine Agonists; Female; Humans; Immunoassay; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 1; Lipids; Luminescent Measurements; Male; Middle Aged; Prolactin; Prolactinoma; Waist Circumference; Young Adult | 2011 |
Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women.
Topics: Adult; Blood Glucose; Bromocriptine; C-Reactive Protein; Cholesterol; Endothelium, Vascular; Estrogens; Female; Fibrinogen; Glucose Tolerance Test; Homocysteine; Hormone Antagonists; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Premenopause; Prolactin; Uric Acid; Vasodilation | 2003 |
Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women.
Topics: Adult; Blood Glucose; Bromocriptine; Calorimetry, Indirect; Circadian Rhythm; Cross-Over Studies; Dopamine Agonists; Eating; Energy Metabolism; Fatty Acids, Nonesterified; Female; Humans; Insulin; Insulin Resistance; Metabolic Syndrome; Middle Aged; Nitrogen; Obesity; Oxygen Consumption; Prolactin; Receptors, Dopamine D2; Urea | 2006 |
22 other study(ies) available for bromocriptine and Insulin Resistance
| Article | Year |
|---|---|
Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
Topics: Alopecia; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Fibrinogen; Humans; Insulin Resistance; Male; Prolactin; Risk Factors; Testosterone; Triglycerides; Uric Acid | 2023 |
[Restriction of breastfeeding in the early postnatal period leads to metabolic and endocrine disorders in eighteen-month-old male rats.]
Topics: Animals; Bromocriptine; Female; Insulin Resistance; Lactation; Male; Metabolic Syndrome; Rats; Thyroid Hormones | 2022 |
Various and sundry recent publications.
Topics: Bromocriptine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Heart Rate; Humans; Insulin Resistance; Obesity | 2021 |
Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
Topics: Adult; Aged; Animals; Bariatric Surgery; Bromocriptine; Cohort Studies; Diabetes Mellitus, Type 2; Disease Models, Animal; Dopamine; Dopamine Agonists; Female; Humans; Insulin Resistance; Intra-Abdominal Fat; Lipid Metabolism; Male; Metabolic Networks and Pathways; Metabolome; Metabolomics; Middle Aged; Obesity; Rats; Receptors, Dopamine D2 | 2021 |
Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.
Topics: Animals; Bromocriptine; Cardiovascular Diseases; Circadian Rhythm; Diet, High-Fat; Hormone Antagonists; Hypertension; Insulin Resistance; Male; Metabolic Syndrome; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley | 2021 |
Does bromocriptine play a role in decreasing oxidative stress for early weaned programmed obesity?
Topics: Adiposity; Animals; Bromocriptine; Dyslipidemias; Female; Glucose; Injections, Intraperitoneal; Insulin Resistance; Intra-Abdominal Fat; Liver; Liver Diseases; Male; Obesity; Oxidation-Reduction; Oxidative Stress; Prolactin; Rats; Rats, Wistar; Time Factors; Weaning | 2014 |
Young female with acromegaloid features and pituitary macroadenoma: what is your diagnosis?
Topics: Acanthosis Nigricans; Acromegaly; Adult; Bromocriptine; Cabergoline; Diagnosis, Differential; Ergolines; Female; Gastrointestinal Diseases; Hirsutism; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prognathism; Prolactinoma | 2014 |
[The influence of two-month treatment with bromocryptine on activity of the adenylyl cyclase signaling system in the myocardium and testes of rats with type 2 diabetes mellitus].
Topics: Adenylyl Cyclases; Administration, Oral; Animals; Blood Glucose; Bromocriptine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dioxoles; Dopamine Agonists; Drug Administration Schedule; Ethanolamines; Guanylyl Imidodiphosphate; Humans; Insulin Resistance; Isoproterenol; Male; Myocardium; Norepinephrine; Rats; Rats, Wistar; Relaxin; Signal Transduction; Streptozocin; Testis; Triglycerides | 2014 |
Dopaminergic Effects on Brown Adipose Tissue (DEBAT): A prospective physiological study.
Topics: Adipose Tissue, Brown; Adult; Body Temperature; Body Weight; Bromocriptine; Dopamine Agonists; Energy Metabolism; Humans; Insulin Resistance; Male; Prospective Studies; Thermogenesis; Young Adult | 2017 |
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Topics: Adult; Aftercare; Aged; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Bromocriptine; Cabergoline; Cholesterol, HDL; Cholesterol, LDL; Dopamine Agonists; Ergolines; Female; Humans; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metabolome; Middle Aged; Obesity; Prevalence; Prolactinoma; Waist Circumference; Weight Gain; Young Adult | 2011 |
Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice.
Topics: Animals; Behavior, Animal; Body Weight; Bromocriptine; Dietary Fats; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Energy Metabolism; Haloperidol; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Motor Activity; Obesity; Phenotype; Random Allocation; Receptors, Dopamine D2; Synaptic Transmission | 2011 |
Inhibition of growth hormone excess reduces insulin resistance and ovarian dysfunction in a lean case of polycystic ovary syndrome with a growth-hormone-producing pituitary adenoma.
Topics: Acanthosis Nigricans; Acromegaly; Adenoma; Adult; Bromocriptine; Dopamine Agents; Female; Glucose Tolerance Test; Human Growth Hormone; Humans; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Lisuride; Magnetic Resonance Imaging; Menstrual Cycle; Ovary; Pancreatic Function Tests; Pituitary Function Tests; Pituitary Neoplasms; Polycystic Ovary Syndrome; Theca Cells | 2003 |
Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome.
Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Body Height; Body Mass Index; Bromocriptine; Cabergoline; Combined Modality Therapy; Ergolines; Female; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Headache; Hormone Antagonists; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Male; Menstruation Disturbances; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Treatment Outcome | 2007 |
Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus).
Topics: Animals; Blood Glucose; Bromocriptine; Circadian Rhythm; Cricetinae; Disease Models, Animal; Energy Metabolism; Fatty Acids, Nonesterified; Female; Glucose; Hormone Antagonists; Hyperinsulinism; Insulin; Insulin Resistance; Lipolysis; Liver; Mesocricetus; Obesity; Oxidation-Reduction; Seasons | 1995 |
Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters.
Topics: Adipose Tissue; Animals; Biogenic Monoamines; Body Composition; Bromocriptine; Chromatography, High Pressure Liquid; Circadian Rhythm; Cricetinae; Dopamine; Glucose Intolerance; Homovanillic Acid; Hydroxyindoleacetic Acid; Hypothalamus, Middle; Insulin Resistance; Male; Methoxyhydroxyphenylglycol; Microdialysis; Obesity; Serotonin | 1998 |
Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters.
Topics: Animals; Blood Glucose; Bromocriptine; Cricetinae; Glucose Clamp Technique; Glucose Intolerance; Injections, Intraventricular; Insulin; Insulin Resistance; Male; Mesocricetus; Obesity; Photoperiod; Weight Gain | 1999 |
Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster.
Topics: Animals; Biogenic Monoamines; Blood Glucose; Body Weight; Bromocriptine; Circadian Rhythm; Cricetinae; Dopamine; Dopamine Agonists; Fatty Acids, Nonesterified; Glucose Intolerance; Glucose Tolerance Test; Hormones; Hypoglycemic Agents; Insulin Resistance; Male; Mesocricetus; Obesity; Serotonin; Suprachiasmatic Nucleus | 2000 |
Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.
Topics: Abdomen; Adipose Tissue; Blood Glucose; Bromocriptine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Male; Middle Aged; Obesity; Prolactin; Skin | 2000 |
Are the results really different?
Topics: Blood Glucose; Bromocriptine; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Humans; Insulin Resistance; Obesity | 2000 |
Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Bromocriptine; Cricetinae; Female; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Insulin Resistance; Mesocricetus; Obesity; Seasons | 1991 |
[Glucose intolerance in pituitary disease].
Topics: Acromegaly; Bromocriptine; Cushing Syndrome; Glucagon; Gluconeogenesis; Glucose; Glucose Tolerance Test; Humans; Hypopituitarism; Insulin Resistance; Liver | 1991 |
Acromegaly and insulin resistance: a case study.
Topics: Acromegaly; Adenoma, Acidophil; Bromocriptine; C-Peptide; Female; Glucagon; Glucose; Glucose Tolerance Test; Growth Hormone; Humans; Insulin; Insulin Resistance; Middle Aged; Pituitary Neoplasms; Tomography, X-Ray Computed | 1986 |